[show abstract][hide abstract] ABSTRACT: This case report describes a patient with a locally advanced oropharyngeal cancer with a simultaneous paraneoplastic encephalomyelitis. To the best of our knowledge, a paraneoplastic neurological syndrome is a rare complication in head and neck cancer, and has previously not been reported in the literature. One year later, following initial treatment, a small cell lung cancer developed, a tumor frequently associated with this type of paraneoplastic syndrome. The dilemma, therefore, is whether this paraneoplastic symdrome was a secondary complication of the tonsilar concurrent cancer or a metachronous paraneoplastic syndrome prior to small cell lung cancer.
[show abstract][hide abstract] ABSTRACT: Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer treatment and its incidence is growing. It significantly affects quality of life and is a dose-limiting factor that interferes with treatment. Its diagnosis can be established in clinical terms but some complementary tests can help when the diagnosis is difficult. There is still no proven method to prevent it that has become a standard of care in spite of the huge amount of investigation carried out in recent years. There are promising strategies that could help reduce the burden of this complication. This review will suggest an approach to the diagnosis of these disorders and provide an update on new therapies.
Clinical and Translational Oncology 02/2010; 12(2):81-91. · 1.28 Impact Factor
[show abstract][hide abstract] ABSTRACT: BackgroundVenous thromboembolism (VTE) is one of the most common complications in cancer patients. It is not only associated with both
reduced survival and a high number of recurrences, but an idiopathic VTE also increases the likelihood of a cancer diagnosis.
MethodsBetween January 2000 and October 2005 we reviewed the medical history of 88 patients who were admitted to a tertiary hospital
and presented both a diagnosis of VTE and any type of tumour. The information collected included the type of tumour, the temporal
association between tumour diagnosis and VTE, anticoagulation treatment applied and percentage of recurrences.
ResultsTen patients (11.4%) presented the VTE prior to the cancer diagnosis; only half of them underwent a posterior tumour screening
routine. Fifteen patients (17%) were diagnosed simultaneously and 71% presented the VTE after the tumour was detected. In
47 patients (53.4%) no risk factors for VTEs were detected. Twenty-nine patients (31.7%) presented a recurrent VTE, mainly
during chemotherapy treatment (66%). Less than half of the patients (47.57%) were receiving treatment with low-molecular-weight
ConclusionsIdiopathic VTEs may be the first manifestation of an occult neoplasia, but tumour screening is scheduled in only a few patients.
Regarding the high incidence of recurrent VTE in cancer populations, a high percentage is attributed to the underuse of LMWH,
whose efficacy in preventing recurrent phenomena is superior to oral dicumarinics.
Clinical and Translational Oncology 09/2008; 10(10):665-669. · 1.28 Impact Factor
[show abstract][hide abstract] ABSTRACT: Malignant fibrous histiocytoma is an aggressive tumor, the most common soft-tissue sarcoma of adult age. It is usually located in the extremities and retroperitoneum, and very rarely there is skeletal involvement. Surgery is the preferred treatment in early disease; in advanced disease, chemotherapy is the main therapeutic strategy. We present a 25-year-old female patient diagnosed with a vertebral mass in T5 with a severely compromised spinal cord. She underwent surgical decompression and the pathological findings were consistent with malignant fibrous histiocytoma. After several surgical treatments she had pulmonary progression and was therefore started on chemotherapy. She had a very poor response to most of the administered regimens until she initiated trabectedin 1 mg/m 2 every three weeks. She showed a significant improvement with a major response of the lung metastases. This report indicates that trabectedin is an active drug in advanced, previously treated metastatic malignant fibrous histiocytoma.
[show abstract][hide abstract] ABSTRACT: Colorectal cancer (CRC) is the most common malignant tumor in Western countries. Despite efforts made to implement screening programmes for early detection and treatment, still half of the patients present or will eventually develop distant metastasis. Management of advanced CRC should be discussed within an experienced multidisciplinary team, to adequately select the most appropriate systemic therapeutic option, as well as the optimal way to integrate it with surgical procedures when indicated. Disease localization and extent, resectability of primary and metastatic disease, tumor biology and dynamics, clinical symptoms, personal preferences and patient’s ability to tolerate intensive chemotherapy or extensive surgical procedures are the key factors to properly design a customized treatment plan. The aim of the current manuscript is to provide synthetic practical guidelines regarding therapeutic options for advanced CRC.
Clinical and Translational Oncology · 1.28 Impact Factor